Dr. James A. Wallace
Medical Oncology (Medical Oncology Physician)
5841 S Maryland Ave
Chicago, IL 60637
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Vermont College of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 429
Licensed in Illinois since 2005, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Vermont College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
IL license 036113259 (first issued 2005; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northwestern Medicine Central Dupage Hospital Winfield, IL
- The University of Chicago Medical Center Chicago, IL
- Ingalls Memorial Hospital Harvey, IL
- Uchicago Medicine Northwest Indiana Crown Point, IN
Medical groups
- Ucm Medical Group Sub LLC (109 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 429
- Services billed
- 2,431
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,158 | 313 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 208 | 84 |
| Established patient office or other outpatient visit, 40-54 minutes | 146 | 87 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 121 | 62 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 38 | 37 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 33 | 32 |
| New patient office or other outpatient visit, 60-74 minutes | 26 | 26 |
| Established patient office or other outpatient visit, 20-29 minutes | 20 | 19 |
| Telephone medical discussion with physician, 11-20 minutes | 16 | 13 |
| New patient office or other outpatient visit, 45-59 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Chicago, IL | 116 |
| Eliquis (apixaban) Other prescribers in Chicago, IL | 91 |
| Warfarin Sodium Other prescribers in Chicago, IL | 57 |
| Prochlorperazine Maleate Other prescribers in Chicago, IL | 55 |
| Anastrozole Other prescribers in Chicago, IL | 52 |
| Xarelto (rivaroxaban) Other prescribers in Chicago, IL | 45 |
| Lenalidomide | 37 |
| Ondansetron Hcl Other prescribers in Chicago, IL | 36 |
| Gabapentin Other prescribers in Chicago, IL | 35 |
| Revlimid (lenalidomide) | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 95 payments worth $21,715 in total to this clinician.
| Jazz Pharmaceuticals Inc. | $19,708 |
|---|---|
| Celgene Corporation | $350 |
| Novartis Pharmaceuticals Corporation | $254 |
| Incyte Corporation | $181 |
| Genentech USA, Inc. | $147 |
| Pfizer Inc. | $141 |
| AstraZeneca Pharmaceuticals LP | $100 |
| GlaxoSmithKline, LLC. | $95.60 |
| Compensation for services other than consulting (speaking, faculty) | $17,670 |
|---|---|
| Food and Beverage | $2,291 |
| Travel and Lodging | $1,661 |
| Education | $92.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) ZEPZELCA · HEMATOLOGY/ONCOLOGY | $4,960 |
| Jazz Pharmaceuticals Inc. Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) ZEPZELCA · HEMATOLOGY/ONCOLOGY | $4,960 |
| Jazz Pharmaceuticals Inc. Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) ZEPZELCA · HEMATOLOGY/ONCOLOGY | $4,960 |
| Jazz Pharmaceuticals Inc. Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) ZEPZELCA · HEMATOLOGY/ONCOLOGY | $2,790 |
| Jazz Pharmaceuticals Inc. Apr 26, 2025 | Travel and Lodging ZEPZELCA · HEMATOLOGY/ONCOLOGY · travel to Quincy, IL · in-kind | $1,101 |
| Jazz Pharmaceuticals Inc. Apr 26, 2025 | Travel and Lodging ZEPZELCA · HEMATOLOGY/ONCOLOGY · travel to Quincy, IL · in-kind | $237 |
| Jazz Pharmaceuticals Inc. May 7, 2025 | Travel and Lodging ZEPZELCA · HEMATOLOGY/ONCOLOGY · travel to Quincy, IL · in-kind | $185 |
| Jazz Pharmaceuticals Inc. Dec 9, 2025 | Travel and Lodging ZEPZELCA · HEMATOLOGY/ONCOLOGY · travel to Granger, IN · in-kind | $137 |
| Incyte Corporation Sep 1, 2025 | Education | $92.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $2,200 in research payments for these studies, mostly to the institutions running them.
- Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
AbbVie Inc. · Active, not recruiting · NCT03539536
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.